Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Crohn’s Disease - Université de Lorraine Access content directly
Journal Articles Gastroenterology Year : 2022

Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Crohn’s Disease

Bruce Sands
Jaroslaw Kierkus
  • Function : Author
Peter Higgins
  • Function : Author
Monika Fischer
  • Function : Author
Vipul Jairath
  • Function : Author
Fumihito Hirai
  • Function : Author
Geert d'Haens
  • Function : Author
Ruth Belin
  • Function : Author
Debra Miller
  • Function : Author
Elisa Gomez-Valderas
  • Function : Author
April Naegeli
  • Function : Author
Jay Tuttle
  • Function : Author
Paul Pollack
  • Function : Author
William Sandborn
  • Function : Author
Peter D.R. Higgins
  • Function : Author
Geert D’haens
  • Function : Author

Abstract

Mirikizumab is a humanized monoclonal antibody targeting interleukin 23p19 with demonstrated efficacy in psoriasis and ulcerative colitis. We investigated the safety and efficacy of mirikizumab in patients with moderate-to-severe Crohn's disease (CD).

Keywords

Dates and versions

hal-04165932 , version 1 (19-07-2023)

Identifiers

Cite

Bruce Sands, Laurent Peyrin-Biroulet, Jaroslaw Kierkus, Peter Higgins, Monika Fischer, et al.. Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Crohn’s Disease. Gastroenterology, 2022, 162 (2), pp.495-508. ⟨10.1053/j.gastro.2021.10.050⟩. ⟨hal-04165932⟩

Collections

UNIV-LORRAINE
7 View
0 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More